|
1
|
Luthra S, Narayanan R, Marques LE, Chwa M,
Kim DW, Dong J, Seigel GM, Neekhra A, Gramajo AL, Brown DJ, et al:
Evaluation of in vitro effects of bevacizumab (Avastin) on
retinal pigment epithelial, neurosensory retinal, and microvascular
endothelial cells. Retina. 26:512–518. 2006.PubMed/NCBI
|
|
2
|
Garg S, Brod R, Kim D, Lane RG, Maguire J
and Fischer D: Retinal pigment epithelial tears after intravitreal
bevacizumab injection for exudative age-related macular
degeneration. Clin Experiment Ophthalmol. 36:252–256. 2008.
View Article : Google Scholar
|
|
3
|
Forooghian F, Cukras C and Chew EY:
Retinal angiomatous proliferation complicated by pigment epithelial
tear following intravitreal bevacizumab treatment. Can J
Ophthalmol. 43:246–248. 2008. View
Article : Google Scholar
|
|
4
|
Shima C, Sakaguchi H, Gomi F, Kamei M,
Ikuno Y, Oshima Y, Sawa M, Tsujikawa M, Kusaka S and Tano Y:
Complications in patients after intravitreal injection of
bevacizumab. Acta Ophthalmol. 86:372–376. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Arias L, Caminal JM, Rubio M, Pujol O and
Arruga J: Retinal pigment epithelial tears after intravitreal
bevacizumab injection for predominantly classic choroidal
neovascularization. Eur J Ophthalmol. 17:992–995. 2007.
|
|
6
|
Subramanyam A, Phatak S and Chudgar D:
Large retinal pigment epithelium rip following serial intravitreal
injection of avastin in a large fibrovascular pigment epithelial
detachment. Indian J Ophthalmol. 55:483–486. 2007. View Article : Google Scholar
|
|
7
|
Spitzer MS, Wallenfels-Thilo B, Sierra A,
Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU and Szurman P;
Tuebingen Bevacizumab Study Group. Antiproliferative and cytotoxic
properties of bevacizumab on different ocular cells. Br J
Ophthalmol. 90:1316–1321. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brar VS, Sharma RK, Murthy RK and Chalam
KV: Evaluation of differential toxicity of varying doses of
bevacizumab on retinal ganglion cells, retinal pigment epithelial
cells, and vascular endothelial growth factor-enriched choroidal
endothelial cells. J Ocul Pharmacol Ther. 25:507–511. 2009.
View Article : Google Scholar
|
|
9
|
Attar-Schneider O, Drucker L, Zismanov V,
Tartakover-Matalon S, Rashid G and Lishner M: Bevacizumab
attenuates major signaling cascades and eIF4E translation
initiation factor in multiple myeloma cells. Lab Invest.
92:178–190. 2012. View Article : Google Scholar
|
|
10
|
Mueller A, Odze R, Jenkins TD, Shahsesfaei
A, Nakagawa H, Inomoto T and Rustgi AK: A transgenic mouse model
with cyclin D1 overexpression results in cell cycle, epidermal
growth factor receptor, and p53 abnormalities. Cancer Res.
57:5542–5549. 1997.PubMed/NCBI
|
|
11
|
Yoo YA, Kim MJ, Park JK, Chung Young Min,
Jong HL, Sung-Gil C, Jun SK and Young DY: Mitochondrial ribosomal
protein L41 suppresses cell growth in association with p53 and
p27Kip1. Mol Cell Biol. 25:6603–6616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Masamha CP and Benbrook DM: Cyclin D1
degradation is sufficient to induce G1 cell cycle arrest despite
constitutive expression of cyclin E2 in ovarian cancer cells.
Cancer Res. 69:6565–6572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yu Q, Geng Y and Sicinski P: Specific
protection against breast cancers by cyclin D1 ablation. Nature.
411:1017–1021. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sherr CJ and Roberts JM: Inhibitors of
mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149–1163.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sherr CJ: The Pezcoller lecture: cancer
cell cycles revisited. Cancer Res. 60:3689–3695. 2000.PubMed/NCBI
|
|
16
|
Vivar OI, Lin C, Firestone GL and
Bjeldanes LF: 3,3′-Diindolylmethane induces a G1 arrest in human
prostate cancer cells irrespective of androgen receptor and p53
status. Biochem Pharmacol. 78:469–476. 2009.
|
|
17
|
Jinno S, Hung SC and Okayama H: Cell cycle
start from quiescence controlled by tyrosine phosphorylation of
Cdk4. Oncogene. 18:565–571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Das SK, Hashimoto T and Kanazawa K: Growth
inhibition of human hepatic carcinoma HepG2 cells by fucoxanthin is
associated with down-regulation of cyclin D. Biochim Biophys Acta.
1780:743–749. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ukomadu C and Dutta A: p21-dependent
inhibition of colon cancer cell growth by mevastatin is independent
of inhibition of G1 cyclin-dependent kinases. J Biol Chem.
278:43586–43594. 2003. View Article : Google Scholar : PubMed/NCBI
|
